Carpal Tunnel Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major carpal tunnel syndrome markets reached a value of US$ 427.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 637.8 Million by 2034, exhibiting a growth rate (CAGR) of 3.7% during 2024-2034.
The carpal tunnel syndrome market has been comprehensively analyzed in IMARC's new report titled "Carpal Tunnel Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Carpal tunnel syndrome refers to a disorder that occurs when the median nerve, which extends from the forearm into the hand, becomes squeezed or compressed while it passes through the carpal tunnel in the wrist. Some of the common indications include numbness or tingling sensations in the index, thumb, middle, and half of the ring fingers. There may be pain or discomfort that can radiate up the forearm or to the shoulder. Many patients might experience a sensation of swelling in the fingers, even if there is no visible swelling. Symptoms often worsen at night or upon waking up and may be temporarily relieved by shaking or moving the hand and fingers. The diagnosis of carpal tunnel syndrome involves a comprehensive evaluation that includes a medical history review, a physical examination, and potentially diagnostic tests. Healthcare professionals will inquire about the indications as well as any relevant medical conditions or activities that may contribute to the ailment. Tapping or pressing on the median nerve in the wrist (Tinel's sign) or flexing the wrist for an extended period (Phalen's maneuver) can elicit characteristic symptoms. Several diagnostic procedures, such as nerve conduction studies and electromyography, are also adopted to measure nerve function and assess the severity of the ailment.
The rising cases of trauma or repetitive stress injuries to the wrist area, which result in compression of the median nerve, are primarily driving the carpal tunnel syndrome market. In addition to this, the widespread adoption of several medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, to reduce pain and inflammation associated with the ailment is acting as another significant growth-inducing factor. Moreover, the increasing utilization of ultrasound-guided interventions for improved precision and effectiveness in targeting specific anatomical structures, including the median nerve, tendons, ligaments, etc., is creating a positive outlook for the market. Apart from this, the escalating usage of neuromodulation techniques, such as transcutaneous electrical nerve stimulation (TENS) and repetitive magnetic stimulation (rMS), that aim to modulate nerve activity as well as help to reduce pain perception is also augmenting the market growth. Additionally, the emerging popularity of extracorporeal shockwave therapy (ESWT), since it promotes blood flow, increases cellular metabolism, and induces the release of growth factors, which can facilitate tissue repair as well as regeneration in the affected area, is expected to drive the carpal tunnel syndrome market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the carpal tunnel syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for carpal tunnel syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the carpal tunnel syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the carpal tunnel syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the carpal tunnel syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current carpal tunnel syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Key Questions Answered in this Report:
Market Insights
How has the carpal tunnel syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the carpal tunnel syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the carpal tunnel syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of carpal tunnel syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of carpal tunnel syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of carpal tunnel syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with carpal tunnel syndrome across the seven major markets?
What is the size of the carpal tunnel syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of carpal tunnel syndrome?
What will be the growth rate of patients across the seven major markets?
Carpal Tunnel Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for carpal tunnel syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the carpal tunnel syndrome market?
What are the key regulatory events related to the carpal tunnel syndrome market?
What is the structure of clinical trial landscape by status related to the carpal tunnel syndrome market?
What is the structure of clinical trial landscape by phase related to the carpal tunnel syndrome market?
What is the structure of clinical trial landscape by route of administration related to the carpal tunnel syndrome market?
The carpal tunnel syndrome market has been comprehensively analyzed in IMARC's new report titled "Carpal Tunnel Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Carpal tunnel syndrome refers to a disorder that occurs when the median nerve, which extends from the forearm into the hand, becomes squeezed or compressed while it passes through the carpal tunnel in the wrist. Some of the common indications include numbness or tingling sensations in the index, thumb, middle, and half of the ring fingers. There may be pain or discomfort that can radiate up the forearm or to the shoulder. Many patients might experience a sensation of swelling in the fingers, even if there is no visible swelling. Symptoms often worsen at night or upon waking up and may be temporarily relieved by shaking or moving the hand and fingers. The diagnosis of carpal tunnel syndrome involves a comprehensive evaluation that includes a medical history review, a physical examination, and potentially diagnostic tests. Healthcare professionals will inquire about the indications as well as any relevant medical conditions or activities that may contribute to the ailment. Tapping or pressing on the median nerve in the wrist (Tinel's sign) or flexing the wrist for an extended period (Phalen's maneuver) can elicit characteristic symptoms. Several diagnostic procedures, such as nerve conduction studies and electromyography, are also adopted to measure nerve function and assess the severity of the ailment.
The rising cases of trauma or repetitive stress injuries to the wrist area, which result in compression of the median nerve, are primarily driving the carpal tunnel syndrome market. In addition to this, the widespread adoption of several medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, to reduce pain and inflammation associated with the ailment is acting as another significant growth-inducing factor. Moreover, the increasing utilization of ultrasound-guided interventions for improved precision and effectiveness in targeting specific anatomical structures, including the median nerve, tendons, ligaments, etc., is creating a positive outlook for the market. Apart from this, the escalating usage of neuromodulation techniques, such as transcutaneous electrical nerve stimulation (TENS) and repetitive magnetic stimulation (rMS), that aim to modulate nerve activity as well as help to reduce pain perception is also augmenting the market growth. Additionally, the emerging popularity of extracorporeal shockwave therapy (ESWT), since it promotes blood flow, increases cellular metabolism, and induces the release of growth factors, which can facilitate tissue repair as well as regeneration in the affected area, is expected to drive the carpal tunnel syndrome market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the carpal tunnel syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for carpal tunnel syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the carpal tunnel syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the carpal tunnel syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the carpal tunnel syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current carpal tunnel syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Key Questions Answered in this Report:
Market Insights
How has the carpal tunnel syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the carpal tunnel syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the carpal tunnel syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of carpal tunnel syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of carpal tunnel syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of carpal tunnel syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with carpal tunnel syndrome across the seven major markets?
What is the size of the carpal tunnel syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of carpal tunnel syndrome?
What will be the growth rate of patients across the seven major markets?
Carpal Tunnel Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for carpal tunnel syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the carpal tunnel syndrome market?
What are the key regulatory events related to the carpal tunnel syndrome market?
What is the structure of clinical trial landscape by status related to the carpal tunnel syndrome market?
What is the structure of clinical trial landscape by phase related to the carpal tunnel syndrome market?
What is the structure of clinical trial landscape by route of administration related to the carpal tunnel syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CARPAL TUNNEL SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CARPAL TUNNEL SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CARPAL TUNNEL SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CARPAL TUNNEL SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CARPAL TUNNEL SYNDROME - UNMET NEEDS
10 CARPAL TUNNEL SYNDROME - KEY ENDPOINTS OF TREATMENT
11 CARPAL TUNNEL SYNDROME - MARKETED PRODUCTS
11.1 List of Carpal Tunnel Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CARPAL TUNNEL SYNDROME - PIPELINE DRUGS
12.1 List of Carpal Tunnel Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CARPAL TUNNEL SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CARPAL TUNNEL SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CARPAL TUNNEL SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Carpal Tunnel Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Carpal Tunnel Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Carpal Tunnel Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Carpal Tunnel Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Carpal Tunnel Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Carpal Tunnel Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Carpal Tunnel Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Carpal Tunnel Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
16 CARPAL TUNNEL SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CARPAL TUNNEL SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CARPAL TUNNEL SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CARPAL TUNNEL SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CARPAL TUNNEL SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CARPAL TUNNEL SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CARPAL TUNNEL SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CARPAL TUNNEL SYNDROME - UNMET NEEDS
10 CARPAL TUNNEL SYNDROME - KEY ENDPOINTS OF TREATMENT
11 CARPAL TUNNEL SYNDROME - MARKETED PRODUCTS
11.1 List of Carpal Tunnel Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CARPAL TUNNEL SYNDROME - PIPELINE DRUGS
12.1 List of Carpal Tunnel Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CARPAL TUNNEL SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CARPAL TUNNEL SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CARPAL TUNNEL SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Carpal Tunnel Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Carpal Tunnel Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Carpal Tunnel Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Carpal Tunnel Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Carpal Tunnel Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Carpal Tunnel Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Carpal Tunnel Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Carpal Tunnel Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Carpal Tunnel Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Carpal Tunnel Syndrome - Access and Reimbursement Overview
16 CARPAL TUNNEL SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CARPAL TUNNEL SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CARPAL TUNNEL SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
